Back to results
US 5,614,492 AGranted
Insulinotropic hormone GLP-1 (7-36) and uses thereof
AssigneeThe General Hospital Corporation
InventorJoel F. Habener
Life of this patent
Estimating the term…
Abstract
Derivatives of glucagon-like peptide I (GLP-1) and especially GLP-1(7-36) have been found to have insulinotropic activity. The invention pertains to the use of GLP-1(7-36) for the treatment of type II diabetes mellitus.
Claims16
A method for treating type II diabetes mellitus in an individual in need of such treatment, said method comprising
- administering to said individual an effective amount of an insulinotropic molecule which is sufficient to treat said diabetes;
- wherein said insulinotropic molecule is selected from the group consisting of:
- (A) a glueagon-like peptide-1(7-36), GLP-1(7-36) having the amino acid sequence:
- His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala -Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg;
- and
- (B) a derivative of said GLP-1(7-36) (A), wherein said derivative is selected from the group consisting of:
- (1) a pharmaceutically acceptable acid addition salt of said GLP-1(7-36);
- (2) a pharmaceutically acceptable carboxylate salt of said GLP-1(7-36);
- (3) a pharmaceutically acceptable lower alkyl ester of said GLP-1(7-36);
- and,
- (4) a pharmaceutically acceptable amide of said GLP-1(7-36);
- and wherein (i) said insulinotropic molecule has an insulinotropic activity which exceeds the insulinotropic activity of glucagon-like peptide-1(1-36). GLP-1(1-36), or glucagon-like peptide-1(1-37), GLP-1(1-37);
- and (ii) said insulinotropic molecule is combined in admixture with a suitable pharmaceutically acceptable carrier.
10 more elements
A method for enhancing the expression of insulin in a pancreatic .beta.-type islet cell, comprising
- providing to a mammalian pancreatic .beta.-type islet cell an effective amount of an insulinotropic molecule selected from the group consisting of:
- (A) a glucagon-like peptide-1(7-36), GLP-1(7-36), having the amino acid sequence:
- His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala -Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg;
- and
- (B) a derivative of said GLP-1(7-36) (A), wherein said derivative is selected from the group consisting of:
- (1) a pharmaceutically acceptable acid addition salt of said GLP-1(7-36);
- (2) a pharmaceutically acceptable carboxylate salt of said GLP-1(7-36);
- (3) a pharmaceutically acceptable lower alkyl ester of said GLP-1(7-36);
- and,
- (4) a pharmaceutically acceptable amide of said GLP-1(7-36);
- wherein (i) said insulinotropic molecule has an insulinotropic activity which exceeds the insulinotropic activity of glucagon-like peptide-1(1-36), GLP-1(1-36) or glucagon-like peptide-1(1-37), GLP-1(1-37);
- and (ii) said molecule is combined in admixture with a suitable pharmaceutically acceptable carrier.
9 more elements
A method for stimulating insulin secretion from the pancreas in an individual in a hyperglycemic state, said method comprising
- administering to said individual an effective amount of an insulinotropic molecule which is sufficient to stimulate insulin secretion in said individual;
- wherein said insulinotropic molecule is selected from the group consisting of:
- (A) a glucagon-like peptide-1(7-36), GLP-1(7-36), having the amino acid sequence:
- His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala -Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg;
- and
- (B) a derivative of said GLP-1(7-36) (A), wherein said derivative is selected from the group consisting of:
- (1) a pharmaceutically acceptable acid addition salt of said GLP-1(7-36);
- (2) a pharmaceutically acceptable carboxylate salt of said GLP-1(7-36);
- (3) a pharmaceutically acceptable lower alkyl ester of said GLP-1(7-36);
- and,
- (4) a pharmaceutically acceptable amide of said GLP-1(7-36);
- and wherein (i) said insulinotropic molecule has an insulinotropic activity which exceeds the insulinotropic activity of glucagon-like peptide-1(1-36). GLP-1(1-36), or glucagon-like peptide-1(1-37). GLP-1(1-37);
- and (ii) said molecule is combined in admixture with a suitable pharmaceutically acceptable carrier.
10 more elements
Dependencies are inferred from the claim text.